Archive for the ‘ibm watson’ Category
IBM and Salesforce have announced a global strategic partnership to deliver joint solutions designed to leverage artificial intelligence and enable companies to make smarter decisions, faster than ever before.
With the partnership, IBM Watson, the leading AI platform for business, and Salesforce Einstein, AI that powers the world’s #1 CRM, will seamlessly connect to enable an entirely new level of intelligent customer engagement across sales, service, marketing, commerce and more. IBM is also strategically investing in its Global Business Services capabilities for Salesforce with a new practice to help clients rapidly deploy the combined IBM Watson and Salesforce Einstein capabilities.
Salesforce Chairman and CEO, Marc Benioff and IBM Chairman, President and CEO Ginni Rometty announced a global strategic partnership to deliver joint artificial intelligence solutions that will enable companies to make smarter decisions, faster than ever before. (Photo Credit: Jon Simon/Feature Photo Service for IBM)
The partnership will bring new insights from Watson directly into the Salesforce Intelligent Customer Success Platform, combining deep customer insights from Salesforce Einstein with Watson’s structured and unstructured data across many sources and industries including weather, healthcare, financial services and retail.
Together, Watson and Einstein will ingest, reason over and derive recommendations to accelerate decision making and drive greater customer success.
“Within a few years, every major decision—personal or business—will be made with the help of AI and cognitive technologies,” said Ginni Rometty, chairman, president and chief executive officer, IBM. “This year we expect Watson will touch one billion people—through everything from oncology and retail to tax preparation and cars. Now, with today’s announcement, the power of Watson will serve the millions of Salesforce and Einstein customers and developers to provide an unprecedented understanding of customers.”
“The combination of Einstein and Watson will make businesses smarter and our customers more successful,” said Marc Benioff, chairman and CEO, Salesforce. “I’m thrilled to form an alliance with IBM—no company’s core values are as close to Salesforce’s as IBM’s. It’s the best of both worlds.”
Salesforce and IBM will initially deliver the following:
- IBM Watson and Salesforce Einstein Integration: Integrating IBM Watson APIs into Salesforce will bring predictive insights from unstructured data, inside or outside an enterprise, together with predictive insights from customer data delivered by Salesforce Einstein to enable smarter, faster decisions across sales, service, marketing, commerce and more. For example, by combining local shopping patterns, weather and retail industry data from Watson with customer-specific shopping data and preferences from Salesforce Einstein, a retailer will be able to automatically send highly personalized and localized email campaigns to shoppers.
- IBM Weather Insights for Salesforce: The Weather Company, an IBM business, will power a new Lightning component on the Salesforce AppExchange to provide weather insights that inform customer interactions and business performance. For example, an insurance company will be able to pull local forecast data from IBM Weather into Salesforce, and automatically send safety and policy information to customers who are at risk of being impacted by severe weather events.
- IBM Application Integration Suite for Salesforce: Customers will be able to able to bring together on-premise enterprise and cloud data with specialized integration products for Salesforce, surfacing that data directly within the Salesforce Intelligent Customer Success Platform. For example, a wealth advisor will be able to unify client data, such as individual investments and risk profiles, with financial trends and public macroeconomic information from Application Integration Suite right within Salesforce to make smarter decisions for her customers.
- Bluewolf Dedicated Consulting Services and Expertise for Cognitive Solutions, Adding to IBM Strategic Services for Salesforce: Bluewolf, an IBM company, has formed a new practice to help clients rapidly deploy the combined IBM Watson and Salesforce Einstein capabilities. This new unit capitalizes on Bluewolf’s over fifteen years of Salesforce implementations and their current portfolio of multiple Salesforce and Watson projects. Bluewolf will also develop new industry-specific accelerators used by enterprise clients to accelerate adoption of cognitive applications.
As part of the partnership, IBM will deploy Salesforce Service Cloud across the company to transform its global product support services and gain a single, unified view of every IBM customer.
Pricing and Availability
- The IBM Watson and Salesforce Einstein integration is expected to be available in the second half of 2017. Pricing will be announced at the time of general availability.
- IBM Weather Lightning Component on Salesforce AppExchange is expected to be available in the second half of 2017. Pricing will be announced at the time of general availability.
- Bluewolf, an IBM company, expects to offer new industry-focused Solution Accelerators at in the second half of 2017. Pricing will be announced at the time of general availability.
- IBM Application Integration Suite for Salesforce is expected to be available by the end of March 2017. Pricing will be announced at the time of general availability.
IBM Research has announced new research developments in IBM Watson’s ability to detect abnormalities of the eye’s retina.
The Melbourne based IBM researchers have trained a research version of Watson to recognize abnormalities in retina images, which could in the future offer doctors greater insights and speed in their early identification of patients who may be at risk of eye diseases – such as glaucoma, a leading cause of blindness in the developed world.
The research began in 2015 and the latest work has focused on streamlining some of the manual processes experienced by doctors today. This includes distinguishing between left and right eye images, evaluating the quality of retina scans, as well as ranking possible indicators of glaucoma.
Glaucoma has been named “the silent thief of sight” as many patients remain undiagnosed until irreversible vision loss occurs. Glaucoma can be treated but early detection is critical, with doctors currently relying on regular eye examination screening programs.
The researchers applied deep learning techniques and image analytics technology to 88,000 de-identified retina images accessed through EyePACS®, to analyze key anomalies of the eye.
The research results demonstrate Watson’s ability to accurately measure the ratio of the optic cup to disc – which is a key sign of glaucoma – with statistical performance as high as 95 percent. The technology has also been trained to distinguish between left and right eye images (with up to 94 percent confidence), which are important for downstream analysis and for the development effective treatment programs.
The research is expected to continue to improve over time as the research technology expands to detect features of other eye diseases such as diabetic retinopathy and age-related macular degeneration.
You can learn more about IBM Research efforts here.
IBM Launches “Digital – Nation Africa,” Invests $70 Million to Bring Digital Skills to Africa with Free, Watson-Powered Skills Platform
IBM is investing $70 million in building much-needed digital, cloud, and cognitive IT skills to help support a 21st century workforce in Africa.
The initiative, “IBM Digital – Nation Africa”, provides a cloud-based learning platform designed to provide free skills development programs for up to 25 million African youths over five years, enabling digital competence and nurturing innovation in Africa.
This is part of IBM’s global push to build the next generation of skills needed for “New Collar” careers. “New Collar” is a term used by IBM to describe new kinds of careers that do not always require a four-year college degree but rather sought-after skills in cybersecurity, data science, artificial intelligence, cloud, and much more.
For the youth of Africa to be able to benefit from a cognitive future there needs to be a much higher level of digital literacy. At the top of the skills pyramid are developers, who need to know how to create solutions that can leverage the power of cognitive, and entrepreneurs who are aware of the potential.
IBM Digital – Nation Africa is designed to help raise overall digital literacy, increase the number of skilled developers able to tap into cognitive engines and enable entrepreneurs and would be entrepreneurs grow businesses around the new solutions.
Through a free, cloud-based online learning environment delivered on IBM Bluemix, the premier cloud platform for business, the initiative will provide a range of programs from basic IT literacy to highly sought-after advanced IT skills including social engagement, digital privacy, and cyber protection.
Advanced users will be able to explore career-oriented IT topics including programming, cybersecurity, data science and agile methodologies, as well as important business skills like critical thinking, innovation, and entrepreneurship.
The initiative aims to empower African citizens, entrepreneurs, and communities with the knowledge and tools to design, develop, and launch their own digital solutions.
Based on Watson, the cognitive online system will adapt and learn. It will review the multiple interactions the education initiative will have with students, to help direct them to the right courses and help IBM refine the courses to better adapt the material for the needs of the users.
Watson will also create a depth of knowledge using anonymous information gathered from interactions with the students. This will help entrepreneurs and developers understand which current Bluemix solutions best meet their needs and refine their idea to help them design a solution that has greatest market potential.
IBM and Jupiter Medical Center today announced that Jupiter will adopt Watson for Oncology trained by Memorial Sloan Kettering, a cognitive computing platform to provide insights to physicians to help them deliver personalized, evidence-based cancer treatment. Jupiter is the first U.S. community hospital to adopt Watson for Oncology, which will go live at the facility in the beginning of March.
In the U.S., there will be an estimated 1.7M new cancer cases this year, with 125,000 in Florida alone. As healthcare providers and systems seek to enable data-driven, evidence-based cancer care, an explosion of medical information has created both challenges and opportunities to improve quality care. Currently, approximately 50,000 oncology research papers are published annually, and by 2020 medical information is projected to double every 73 days, outpacing the ability of humans to keep up with the proliferation of medical knowledge.
Watson for Oncology provides information to oncologists to help them deliver evidence-based treatment options by analyzing massive volumes of medical literature to identify individualized treatment options and scaling access to oncology expertise.
Watson for Oncology draws from more than 300 medical journals, more than 200 textbooks, and nearly 15 million pages of text to provide insights about different treatment options and also provides oncologists with information regarding drug options and administration instructions. Watson also ranks the evidence-based treatment options, linking to peer reviewed studies and clinical guidelines. Its machine-learning capability means it continuously learns, gaining in value and knowledge over time.
”At Jupiter Medical Center, we are committed to pioneering new approaches to medicine and health care,” said John D. Couris, President and CEO of Jupiter Medical Center. “Watson for Oncology is part of our significant investment in creating a world-class cancer program and we are proud to be the first U.S. community hospital to arm our clinical team with this cutting-edge technology.”
IBM and MSK have been accelerating Watson for Oncology’s training; Watson for Oncology is now available to assist clinicians in developing treatment plans for breast, lung, colorectal, cervical, ovarian and gastric cancers.
IBM and MSK plan to train Watson on at least 9 additional cancer types this year, covering nearly 80 percent of the worldwide incidence of cancer.
“We were impressed by Watson’s analytical ability to help provide relevant treatment options for patients to allow physicians to personalize patient care in an unparalleled way,” said Abraham Schwarzberg, MD, Chief of Oncology at Jupiter Medical Center. “Harnessing the power of Watson will help our oncology multidisciplinary team identify individual treatments. As one of the first in the country to implement this incredible tool, Jupiter Medical Center continues to be a regional leader in integrating technology to provide cutting-edge clinical care.”
You can learn more about IBM Watson Health here.
IBM has announced a new partnership with Ermes Group, the largest and most diversified retailer in Cyprus.
Ermes Group will be leveraging IBM’s Watson Commerce pricing optimization solutions to help ensure product markdowns resonate with value-seeking customers while maximizing profits across all its retail locations relating to Debenhams Department Stores, Next Stores, Oviesse Stores, Peacocks Stores, and Uber Stores.
Product pricing mark downs are a common practice for retailers today. The challenge is identifying the ideal price point and timing of these discounts to deliver cost-conscious customers great deals while avoiding the need to sell items at a loss that erodes potential profits.
This was precisely the issue for Ermes Group, which decided to move from a rather manual approach to IBM’s cloud-based Watson Price Optimization capabilities.
Working with IBM, Ermes is now able to automatically determine which specific products in each store should be marked down due to stagnant sales, what the new price should be and when the reduction should take place.
Previously, teams had to manually go line by line for every product to determine how it was performing and if they should put it on sale. Since going live with IBM, Ermes has significantly streamlined its retail pricing strategy while increasing profits.
“Due to shifts in styles and consumer demands, product markdowns are a reality that all retailers must face. The key is knowing both when to act and what price point will allow the business to still profit on each item left in stock,” said Sophocles Sophocleous, Purchasing Manager of Ermes Department Stores Plc. “With IBM’s cloud offering, our merchandising team can easily and quickly determine which products are lagging in sales and what steps we need to take to get these items moving off the shelf.”
IBM recently released a new study focused on Generation Z, a group that possesses $44 billion in spending power. According to the study, the majority of Generation Z make purchases in the store. Of this group, 66 percent do so because they believe they get good deals and value for their money.
IBM Watson Health has signed a research initiative with the U.S. Food and Drug Administration (FDA) aimed at defining a secure, efficient and scalable exchange of health data using blockchain technology.
IBM and the FDA will explore the exchange of owner mediated data from several sources, such as Electronic Medical Records, clinical trials, genomic data, and health data from mobile devices, wearables and the “Internet of Things.” The initial focus will be on oncology-related data.
Transformative healthcare solutions are possible when healthcare researchers and providers have access to a 360-degree view of patient data. Today, patients have little access to their health data and cannot easily share with researchers or providers.
Giving patients the opportunity to share their data securely, for research purposes or across their healthcare providers, creates opportunities for major advancements in healthcare. Blockchain technology, which enables organizations to work together with more trust, is designed to help make this a reality.
By keeping an audit trail of all transactions on an unalterable distributed ledger, blockchain technology establishes accountability and transparency in the data exchange process. In the past, large scale sharing of health data has been limited by concerns of data security and breaches of patient privacy during the data exchange process.
IBM and the FDA will explore how a blockchain framework can
potentially provide benefits to public health by supporting important use cases for information exchange across a wide variety of data types, including clinical trials and “real world” evidence data.
New insights combining data across the healthcare ecosystem can potentially lead to new biomedical discoveries. Patient data from wearables and connected devices for example, can help doctors and caregivers better manage population health.
The collaboration will also address new ways to leverage the large volumes of diverse data in today’s biomedical and healthcare industries. A secure owner-mediated data sharing ecosystem could potentially hold the promise of new discoveries and improved public health.
The initiative with the FDA is a two-year agreement. IBM Watson Health and the FDA plan to share initial research findings in 2017.
You can learn more about IBM Blockchain capabilities here.
IBM Watson Health and Illumina, Inc. have announced a major partnership to expand access to genome data interpretation by integrating Watson for Genomics into Illumina’s BaseSpace®Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation.
By adding Watson for Genomics to Illumina’s next-generation sequencing platform, researchers who use Illumina’s cancer genome sequencing panel will have rapid access to information to help interpret the broad array of variant data produced by TruSight Tumor 170. Illumina’s TruSight® Tumor 170 is a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes.
In a matter of minutes, Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170, comb professional guidelines, medical literature, clinical trials compendia, and other sources of knowledge to provide information for each genomic alteration, and produce a report for use by researchers — a process that typically takes scientists more than one week to complete.
Watson for Genomics ingests data from approximately 10,000 scientific articles and 100 new clinical trials every month. The Watson for Genomics software will be available to support Illumina’s TruSight Tumor 170 assay early in 2017.
Cancer is a leading cause of death worldwide and a growing body of research shows that analyzing the genomic basis of a tumor can be important for understanding the individual patient’s disease, a major aspect of precision medicine.
However, the output of next generation sequencing panels requires sophisticated analyses to help identify the mutations responsible for cancer growth and correlate that information with potential standard and experimental treatment options. This is where Watson is expected to help.
“To enable precision cancer medicine on a large scale, we need new tools to overcome the data barriers of genomic research,” said Francis deSouza, President and CEO of Illumina.. “With a comprehensive assay of Illumina and the power of Watson, we hope to deliver a rapid turnaround of the genomic alteration results.”
Genome sequencing has increased in recent years following two decades of research demonstrating the promise of precision medicine. However, access to these advances has been limited by the significant time and expense required to interpret the genomic data.